Hairy cell leukaemia

1 trials 1 recruiting MedDRA PT
1 Registered trials
1 Recruiting
1 Unique sponsors
3 Unique IMPs
0 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Antimetabolite 1 substance
Monoclonal antibody (chimeric) 1 substance
RAF/BRAF inhibitor 1 substance
Phase II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase II

1 trial
  • Universita' Degli Studi Di Perugia Academic
    CLADRIBINE; RITUXIMAB; VEMURAFENIB
    2024-520119-41-00 1 country 2023 n=120
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Universita' Degli Studi Di Perugia Academic 1 Phase II 1
New trials by year
2023
1
← All indication landscapes